To: Cooters who wrote (19412 ) 3/3/2001 6:17:07 PM From: Art Bechhoefer Respond to of 60323 Cooters, your conversation with Calderoni was very helpful. Many thanks for your efforts. A couple of points strike me as important. First, the response on royalties from CF and MMC being difficult to estimate seem very evasive. Any company knows, or ought to know what its competitors are doing, and whether its competitors are using any portion of its intellectual property rights. Either SNDK sees infringement and is doing something about it, or its so-called intellectual property rights are unenforceable. Second, and somewhat related to the first, is that, as we already know, SNDK has cross licensing agreements with several major firms, such as Intel. It sounds to me as if SNDK has for all practical purposes gotten into a situation where patented products made and sold by others don't produce ANY royalties because of the all-encompassing cross licensing agreements. Until I hear otherwise, I'm going to assume that most of the SNDK patents no longer can generate substantial royalties--maybe only ten percent or less of total revenues. I will estimate future earnings using this assumption. The lack of royalties leads to a more important issue--whether SNDK is the lowest cost producer, or close to being the lowest cost producer. If so, then we have a commodity business where SNDK is still in the driver's seat. Given the new plant being built in Virginia and the fact that a partner in the venture is Toshiba--a company with a good manufacturing record, it is likely that this plant will be extremely profitable, not just in manufacturing efficiency but also in the type of products to be made in the plant--high capacity cards. Although I'm disappointed that it is so difficult to get any details from SNDK, I think the price targets on the stock, by firms such as Merrill Lynch, are totally unjustified and based on very likely imaginary data. I can't make a very educated guess as to the potential for the stock, but I know that it is considerably more than the $29 target in Merrill's latest advice (dated Feb. 28). That new target replaced an earlier price target of $50. I don't know where they got the data to arrive at that one either. Art